Holen Sie sich die Stockscreener-App
2.91
9.81%
0.26
Handel nachbörslich:
2.96
0.05
+1.72%
Schlusskurs vom Vortag:
$2.65
Offen:
$2.59
24-Stunden-Volumen:
102.02K
Relative Volume:
0.84
Marktkapitalisierung:
$29.04M
Einnahmen:
Nettoeinkommen (Verlust:
$-37.64M
KGV:
-0.6659
EPS:
-4.3698
Netto-Cashflow:
$-33.40M
1W Leistung:
+19.26%
1M Leistung:
+20.25%
6M Leistung:
-49.57%
1J Leistung:
-81.17%
1-Tages-Spanne:
$2.51
$2.95
1-Wochen-Bereich:
$2.30
$3.12
52-Wochen-Spanne:
$1.70
$16.50
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.91 | 29.04M | 0 | -37.64M | -33.40M | -4.3698 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-07 | Eingeleitet | Rodman & Renshaw | Buy |
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa to Issue CVRs Giving Shareholders 25% of Voucher Proceeds - Minichart
Atossa plans CVR issuance tied to priority review voucher By Investing.com - Investing.com South Africa
Atossa Therapeutics Introduces CVR Plan for Voucher Upside - TipRanks
Atossa Plans $50M-Capped CVR for Voucher Proceeds | ATOS Stock News - Stock Titan
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher - PR Newswire
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher - Morningstar
Atossa Therapeutics (Nasdaq:ATOS)Stock Analysis - Simply Wall Street
Debt to equity ratio of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBIT forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Atossa Therapeutics (ATOS) Holds Steady at $2.52 — Awaiting Catalyst Within $2.39–$2.65 RangeTPO Profile - siam.in
Atossa Therapeutics (ATOS) Holds Steady at $2.52 — Awaiting Catalyst Within $2.39–$2.65 RangeSymmetrical Triangle - dars.gov.et
Atossa Therapeutics explores collaborative clinical research for (Z)-endoxifen applications - Traders Union
Atossa (ATOS) Results Breakdown: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: Shares Rise 2.76% at the CloseEarnings Power Value - vinanet.vn
Atossa Therapeutics advances investigational Z-endoxifen research for broader DMD applications - Traders Union
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - Sahm
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma
ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma
Atossa Therapeutics pursues ESR1 mutation research to tackle endocrine resistance in breast cancer - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Atossa Therapeutics shifts clinical focus to pre-surgical breast cancer patients - Traders Union
Atossa Therapeutics (ATOS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock SlipsQuarterly Profit Report - dars.gov.et
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Atossa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView
Atossa Therapeutics reports Q2 2026 results, ad... - Pluang
Atossa Therapeutics (ATOS) Dips 2.48% to $2.36 as Stock Tests Key Support ZoneWyckoff Upthrust - dars.gov.et
Atossa Therapeutics Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Atossa Therapeutics investigates (Z)-endoxifen for McCune-Albright syndrome and endocrine disorders - tradersunion.com
Atossa Therapeutics (ATOS) Advances Clinical Pipeline Amid Valua - GuruFocus
Form 8K Atossa Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
Atossa Therapeutics Q2 net loss widens on lower interest income - TradingView
Atossa Therapeutics reports Q2 2026 net loss $8.5M, cash $26.1M; advances (Z)-endoxifen programs - TradingView
ATOS: Q2 2026 net loss was $8.5M; (Z)-endoxifen programs advanced and $4.5M in new capital raised - TradingView
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary - TradingView
Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk - Stock Titan
Atossa Therapeutics strengthens pipeline with new data on Z-endoxifen breast cancer therapy - tradersunion.com
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Atossa Therapeutics advances rare disease pipeline with (Z)-endoxifen strategy - Traders Union
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Narrows Loss Despite No Revenue; Stock Down 5.48%Financial Health Score - vinanet.vn
Atossa Therapeutics (ATOS) Focuses on Execution Amid Challenging Valuation and Mixed Guru Interest - GuruFocus
Atossa Therapeutics advances biomarker-driven Z-endoxifen treatment for breast cancer - Traders Union
Atossa study shows preclinical activity in breast cancer models By Investing.com - Investing.com South Africa
Atossa Therapeutics (ATOS) Unveils Promising Preclinical Breast Cancer Study Amidst Challenging Valuation - GuruFocus
Atossa study shows preclinical activity in breast cancer models - Investing.com
Atossa study shows preclinical activity in breast cancer models By Investing.com - Investing.com Canada
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):